

LBA68
CCTG BR.31: Adjuvant durvalumab (D) in resected non-small-cell lung cancer (NSCLC): Final overall survival (OS) and minimal residual disease (MRD) analyses

G. Goss¹, G. Darling², V. Westeel³, K. Nakagawa⁴, B. Massuti Sureda⁵, F. Perrone⁶, S-A. McLachlan⁷, J.H. Kang⁸, Y-L. Wu⁹, A-M.C. Dingemans¹⁰, R. Dziadziuszko¹¹, M. Okada¹², L. Greillier¹³, C. Audigier-Valette¹⁴, S. Sugawara¹⁵, E. Nadal¹⁶, A. Catino¹⁷, M.R. Stockler¹⁸, K. Ding¹⁹, C. O'Callaghan²⁰

¹ Medicine, The Ottawa Hospital Research Institute, Ottawa, Canada, ² Surgery, Dalhousie University Canada, Halifax, Canada, ³ Medicine, CHRU Besancon - Hopital Jean Minjoz, Besancon, France, ⁴ Department of Medical Oncology, Kindai University School of Medicine - Main Campus, Osaka, Japan, ⁵ Department of Medical Oncology, Hospital General Universitario Dr. Balmis, Alicante, Spain, ⁶ Clinical Trial Unit, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Naples, Italy, ⁷ Medical Oncology, GenesisCare St Vincent's Hospital, Melbourne, Australia, ⁸ Department of Medical Oncology, The Catholic University of Korea - Seoul St. Mary's Hospital - Catholic Medical Center, Seoul, Republic of Korea, ⁹ Lung Cancer Institute, Guangdong Province People's Hospital, Guangzhou, China, ¹⁰ Pulmonology Department, Erasmus MC - University Medical Center, Rotterdam, Netherlands, ¹¹ Oncology and Radiotherapy Department, Medical University of Gdansk, Gdansk, Poland, ¹² Surgery, Hiroshima University Hospital, Hiroshima, Japan, ¹³ Multidisciplinary Oncology and Therapeutic Innovations, Assistance Publique Hopitaux de Marseille, Marseille, France, ¹⁴ Pneumonology, Hospital Sainte Musse, Toulon, France, ¹⁵ Pulmonary Medicine Department, Sendai Kousei Hospital, Sendai, Japan, ¹⁶ Medical Oncology Department, ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, Spain, ¹⁷ Thoracic Oncology Department, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy, ¹⁸ NHMRC Clinical Trials Centre, NHMRC Clinical Trials Centre, Camperdown, Australia, ¹⁹ Canadian Cancer Trials Group, Kingston, Canada²⁰ Clinical Trial Unit, Canadian Cancer Trials Group, Kingston, Canada

Background

We reported on the primary endpoint of disease-free survival (DFS) in the Canadian Cancer Trials Group BR.31 trial [Ann Oncol 2024; 35 (Supplement 2): S1238]. Here we report the final OS and MRD analyses.

Methods

BR.31 (NCT02273375) was placebo (P) controlled, randomizing 1415 patients (pts) to D v P (2:1). The primary analysis population was pts with PD-L1 TC ≥25%, excluding those with common *EGFR* mutations (Ex19del/L858R) or *ALK* rearrangements (*EGFR*-/*ALK*-). Secondary analyses groups were pts with PD-L1 TC ≥1% and *EGFR*-/*ALK*-, all *EGFR*-/*ALK*- pts and all randomized pts. Retrospective MRD analysis of plasma collected at randomization was performed using the tumour-informed Invitae Personalized Cancer Monitoring™ Test.

Results

OS and MRD results with a median follow-up of 81 months are tabulated below: OS was not improved by adjuvant D v P in any analysis group. MRD status was available for 1131 (D: 762; P: 369) pts (80%): 116 (10%) positive (+) and 1015 negative (-). There was no difference in the effects of D v P on OS comparing pts with/without an MRD result (p=0.75). MRD + was highly negatively prognostic for OS in the P arm of all groups. D significantly improved OS in MRD +, *EGFR*-/*ALK*- pts in both the PD-L1 ≥25% (p=0.011) and >1% (p=0.024) subgroups with the effects of D v P on OS significantly better for MRD + v MRD - pts in all groups (interaction p-values all <0.05).Table: LBA68

Group	N	OS		MRD												Interaction P value							
		Prognostic				Predictive																	
		Deaths	% alive 5 yr	HR	95% CI	P	P arm only MRD + v -	D v P															
MRD + D	P	D	P	MRD -		N	HR	95%CI	p	N	HR	95%CI	p	N	HR	95%CI	p						
PD-L1 ≥25% & EGFR/ALK-	477	88	45	80	80	0.98	0.69-1.42			0.93	128	8.74	4.40-17.35	<0.0001	29	0.30	0.11-0.80	0.011	350	1.28	0.82-2.01	0.28	0.006

Group	N	OS		MRD		Predictive			Interaction P value												
		Prognostic																			
		Deaths	% alive 5 yr	HR	95% CI	P	P arm only MRD + v -	D v P													
MRD + D	P	D	P	MRD - N	HR	95%CI	p	N	HR	95%CI	p	N	HR	95%CI	p						
PD-L1 ≥1% & EGFR/ALK-	709	149	72	76	77	1.10	0.83-1.47	0.52	195	9.14	5.31-15.74	<0.0001	55	0.49	0.26-0.92	0.024	514	1.38	0.97-1.97	0.08	0.003
All EGFR/ALK-	1219	266	135	75	73	1.00	0.81-1.23	0.96	321	7.33	4.84-11.12	<0.0001	97	0.71	0.45-1.12	0.14	887	1.12	0.86-1.45	0.39	0.044
All randomized	1415	298	145	76	75	1.02	0.84-1.25	0.85	369	6.50	4.34-9.73	<0.0001	116	0.72	0.46-1.12	0.14	1015	1.12	0.87-1.44	0.37	0.045

Conclusions

Adjuvant D v P did not improve OS in *EGFR*-/ALK- pts, regardless of PD-L1 status. MRD + status was prognostic for OS and predictive of an OS benefit for treatment with D.

Clinical trial identification

NCT02273375.

Legal entity responsible for the study

Canadian Cancer Trials Group (CCTG).

Funding

Canadian Cancer Society Unrestricted grant from AstraZeneca.

Disclosure

G. Goss: Financial Interests, Personal, Advisory Board, I have participated in advisory boards for AstraZeneca: AstraZeneca; Financial Interests, Personal, Invited Speaker, I gave a talk on immunotherapy in NSCLC: Merck; Financial Interests, Personal, Advisory Board, Scientific Advisor: NewPhase; Non-Financial Interests, Principal Investigator, I am the PI of the BR.31 trial in early stage NSCLC: Canadian Cancer Trials Group. V. Westeel: Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb, Pfizer; Financial Interests, Personal, Other, scientific committee and invited speaker: MSD; Financial Interests, Personal, Invited Speaker, and scientific committee: Roche, Amgen; Financial Interests, Personal, Invited Speaker, and board: Sanofi; Financial Interests, Institutional, Other, local PI: Bristol Myers Squib; Financial Interests, Institutional, Coordinating PI: MSD, Merck; Financial Interests, Institutional, Local PI: Roche, Daiichi, Amgen, Seagen, Ose Immunotherapeutics; Other, Other, support for meeting attendance: AstraZeneca, Bristol Myers Squib, Janssen; Other, Other, Support for meeting attendance: MSD, Amgen. K. Nakagawa: Financial Interests, Personal, Invited Speaker: Ono Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., MSD K.K., Taiho Pharmaceutical Co.,Ltd., Merck Biopharma Co., Ltd., Medical Mobile Communications co., Ltd, Daiichi Sankyo Co., Ltd., Otuka Pharmaceutical Factory, Inc., M3, Inc., Hisamitsu Pharmaceutical Co., Inc., Global Health Consulting Japan Co., Ltd., The Yomiuri Shimbun, Patientricity MedPartners K.K., 3H Medi Solution Inc.; Financial Interests, Personal, Advisory Board: Ono Pharmaceutical Co.,Ltd., Eli Lilly Japan K.K.; Financial Interests, Personal, Writing Engagement: Yodosha Co., Ltd.; Financial Interests, Institutional, Research Grant: Amgen Inc., Bristol Myers Squibb K.K., Chugai Pharmaceutical Co.,Ltd., EPS Corporation., Iqvia Services Japan K.K., MSD K.K., Nippon Boehringer Ingelheim Co.,Ltd., Pra Healthsciences, Syneos Health Clinical K.K., CMIC CO., Ltd., Pfizer R&D Japan G.K., Labcorp Development Japan K.K., Astellas Pharma Inc., Ascent Development Services, AstraZeneca K. K., AbbVie Inc., A2 Healthcare Corp., Japan Clinical Cancer Research Organization, Thoracic Oncology Research Group. F. Perrone: Financial Interests, Personal, Advisory Board: GSK, BMS, Menarini, Roche, Immunocore, Viartis; Financial Interests, Institutional, Research Grant, Financial support for clinical trials promoted by the NCI Naples: Roche, Bayer, AstraZeneca, Merck; Financial Interests, Institutional, Research Grant, Financial support for phase 1 trials at the NCI Naples: Incyte, Tesaro/GSK; Non-Financial Interests, Leadership Role, President (November 2023 to November 2025): AIOM Associazione Italiana di Oncologia Medica. Y. Wu: Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, Boehringer Ingelheim, BeiGene, Hengrui, Merk, MSD, Pfizer, Roche, Sanofi; Financial Interests, Personal, Advisory Board: AstraZeneca, MSD, Takeda, Amgen, Daiichi Sankyo; Financial Interests, Coordinating PI: AstraZeneca, Boehringer Ingelheim, BMS, Hengrui, Merk, MSD, Pfizer, Roche, Eli Lilly; Financial Interests, Steering Committee Member: Sanofi, Yunhan; Non-Financial Interests, Leadership Role: Chinese Thoracic Oncology Group (CTONG); Non-Financial Interests, Other, WCLC 2020 Conference Chair: IASLC; Non-Financial Interests, Leadership Role, Past President: Chinese Society of Clinical Oncology (CSCO); Non-Financial Interests, Other, Editorial

Board member of Ann Oncology and ESMO Open: ESMO. A.C. Dingemans: Financial Interests, Institutional, Advisory Board: Roche, Amgen, Bayer, AstraZeneca, Boehringer Ingelheim, Johnson & Johnson, Mirati, Boehringer Ingelheim, Pfizer, MSD; Financial Interests, Institutional, Invited Speaker: Lilly, Eli Lilly; Financial Interests, Institutional, Other, IDMC: Roche; Financial Interests, Institutional, Research Grant: Amgen; Financial Interests, Institutional, Local PI: Lilly, Amgen, Daiichi, JNJ, Mirati, Bayer; Financial Interests, Institutional, Coordinating PI: Roche; Financial Interests, Institutional, Steering Committee Member: Roche, Eli Lilly, Amgen; Non-Financial Interests, Other, Chair EORTC lung cancer group: EORTC; Non-Financial Interests, Member: IASLC, ASCO, AACR, ERS. R. Dziadziuszko: Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, Pfizer, MSD, Bristol Myers-Squibb, GSK, Jansen, Amgen; Financial Interests, Personal, Officer, Member of Scientific Board: Polish Agency for Medical Research (ABM); Financial Interests, Personal and Institutional, Coordinating PI: Roche, AstraZeneca; Financial Interests, Personal and Institutional, Local PI: MSD, Amgen, Celon Pharma, Pfizer, Novartis, Bristol Myers-Squibb, Eli Lilly, Loxo, Ryvu Therapeutics, Boehringer Ingelheim; Financial Interests, Personal and Institutional, Other, Subinvestigator and ad hoc Consultant: PDC* line Pharma; Financial Interests, Local PI: OSE Immunotherapeutics; Non-Financial Interests, Institutional, Product Samples: Pfizer, Novartis; Non-Financial Interests, Member: American Society of Clinical Oncology, Polish Society of Oncology, Polish Society of Clinical Oncology, Polish Society of Radiation Oncology, Academia Europea, European Society for Radiotherapy and Oncology. L. Greillier: Financial Interests, Personal, Advisory Board: AbbVie, AstraZeneca, BMS, MSD, Novartis, Sanofi, Takeda, Roche, Daiichi Sankyo, Johnson and Johnson; Financial Interests, Personal, Invited Speaker: Lilly, Pfizer, Regeneron; Financial Interests, Institutional, Local PI: AstraZeneca, AbbVie, BMS, MSD, Novartis, Takeda, Pfizer, Roche, PharmaMar, Johnson and Johnson, Boehringer Ingelheim; Financial Interests, Institutional, Coordinating PI: Sanofi, Daiichi Sankyo, Amgen. S. Sugawara: Financial Interests, Personal, Other, Lecture fee: AstraZeneca, Chugai Pharma, Nippon Boehringer Ingelheim, Taiho Pharmaceutical, Pfizer, Lilly, Novartis, Bristol Myers Squibb, Ono Pharmaceutical, MSD K.K, Kyowa Kirin, Takeda, Nippon Kayaku, Merck, Amgen, Thermo Fisher Scientific, Daiichi Sankyo; Financial Interests, Personal, Other, Lecture Fee: Eisai, Sysmex; Financial Interests, Institutional, Local PI: AstraZeneca, Chugai Pharma, MSD K.K, Daiichi Sankyo, Bristol Myers Squibb, AnHeart, Nippon Boehringer Ingelheim, AbbVie, Parexel International, Amgen, Taiho Pharmaceutical, PPD-SNBL, IQVIA, Novocure, PharmaMar, GSK, Delta-Fly Pharma. M.R. Stockler: Financial Interests, Institutional, Research Grant, DASL: Bayer; Financial Interests, Institutional, Research Grant, Enzamet & Enzarad: Astellas; Financial Interests, Institutional, Research Grant, Keypad: Amgen, MSD; Financial Interests, Institutional, Research Grant, NIVORAD: BMS; Financial Interests, Institutional, Research Grant: Pfizer, ROCHE; Financial Interests, Institutional, Research Grant, ADELE: BeiGene; Financial Interests, Institutional, Research Grant, PARAGON2: Novartis; Financial Interests, Institutional, Other, Study Drug for Cannabis CINV Trial: Tilray; Financial Interests, Institutional, Research Grant, ILLUMINATE, PHAEDRA, AstraZeneca. All other authors have declared no conflicts of interest.